1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Solid Tumor Malignancy: new trials by email Literature Review of Solid Tumor Malignancy trials Research Report on Solid Tumor Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Pemigatinib - Solid Tumor Malignancy | Phase 2 | Terminated | Incyte Corporation | 111 | 2019-10-17 | 2025-11-04 |
Bone Diseases (1) · Bone Diseases, Developmental (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Craniofacial Abnormalities (1) · Craniosynostoses (1) · Dysostoses (1) · Limb Deformities, Congenital (1) · Musculoskeletal Abnormalities (1) · Musculoskeletal Diseases (1) · Syndactyly (1) · Synostosis (1)
pemigatinib (1)
Denmark (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Switzerland (1) · United Kingdom (1) · United States (1)
2018 (1)